Abstract: The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.
Type:
Application
Filed:
August 22, 2005
Publication date:
September 6, 2007
Applicant:
WARNER-LAMBERT COMPANY LLC
Inventors:
Stephen Barrett, Daniel Du, Lain-Yen Hu
Abstract: This invention relates to novel tetrazole and oxadiazalone ?-amino acids derivatives of the formula wherein G is wherein R1 through R4 are defined as in the specification, pharmaceutical compositions containing them and their use for the treatment of various central nervous system and other disorders. The cyclopropyl ?-amino acids derivatives of this invention exhibit activity as alpha2delta ligands (?2? ligands). Such compounds have affinity for the ?2? subunit of a calcium channel.
Type:
Grant
Filed:
March 8, 2004
Date of Patent:
July 31, 2007
Assignee:
Warner Lambert Company LLC
Inventors:
Nancy Sue Barta, Norman Lloyd Colbry, Raymond Hudack, Jr., Kristin Knapp Lin, Jacob Bradley Schwarz, Andrew John Thorpe, David Juergen Wustrow, Zhijian Zhu
Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
Type:
Grant
Filed:
February 6, 2004
Date of Patent:
July 17, 2007
Assignee:
Warner Lambert Company LLC
Inventors:
Larry D. Bratton, Xue-Min Cheng, Noe Erasga, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi, Paul C. Unangst
Abstract: The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.
Type:
Application
Filed:
March 19, 2007
Publication date:
July 12, 2007
Applicant:
WARNER-LAMBERT COMPANY LLC
Inventors:
David Dooley, Charles Taylor, Andrew Thorpe, Fong Wang, David Wustrow
Abstract: The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.
Type:
Application
Filed:
March 19, 2007
Publication date:
July 12, 2007
Applicant:
WARNER-LAMBERT COMPANY LLC
Inventors:
David Dooley, Charles Taylor, Jr., Andrew Thorpe, Fong Wang, David Wustrow
Abstract: P-chiral bisphospholane ligands and methods for their preparation are described. Use of metal/P-chiral bisphospholane complexes to catalyze asymmetric transformation reactions to provide high enantiomeric excesses of formed compounds is also described.
Type:
Grant
Filed:
May 10, 2004
Date of Patent:
June 12, 2007
Assignee:
Warner Lambert Company LLC
Inventors:
Garrett Stewart Hoge, II, Om Prakash Goel
Abstract: The invention provides compounds which are PDE7 inhibitors, having the following formula (I), (II) and (III) in which X1, X2, X3, X4, X, Y, Z, A and Z1 are as defined in the description, methods for preparing them and their use for the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.
Type:
Grant
Filed:
May 24, 2004
Date of Patent:
May 8, 2007
Assignee:
Warner-Lambert Company LLC
Inventors:
Patrick Bernardelli, Pierre Ducrot, Edwige Lorthiois, Febrice Vergne
Abstract: The present invention provides compounds of Formula I wherein W, Q, E, D, R6, R7, R8, Y, K, R9, R10, R12, G, and the double bond denoted “*” have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
Abstract: The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss.
Type:
Grant
Filed:
May 10, 2005
Date of Patent:
April 10, 2007
Assignee:
Warner Lambert Company LLC
Inventors:
Yuan-Ching P. Chiang, Gary E. Aspnes, Kimberly G. Estep
Abstract: The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.
Type:
Application
Filed:
November 7, 2006
Publication date:
March 29, 2007
Applicant:
WARNER-LAMBERT COMPANY LLC
Inventors:
Stephen Barrett, Victor Fedij, Lain-Yen Hu, Donna Iula, Bruce Lefker, Raj Raheja, Karen Sexton, Jennifer Van Camp
Abstract: An improved process for the preparation of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide by a novel synthesis is described where methyl cyanoacetate is converted in eight operations or fewer to the desired product, as well as other valuable intermediates used in the process.
Type:
Grant
Filed:
April 19, 2005
Date of Patent:
February 27, 2007
Assignee:
Warner-Lambert Company, LLC
Inventors:
Donald Eugene Butler, Randall Lee DeJong, Jade Douglas Nelson, Michael Gerard Pamment, Timothy Lee Stuk
Abstract: Certain ?-amino acids that bind to the alpha-2-delta (?2?) subunit of a calcium channel are disclosed. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders. Also disclosed are methods of making the ?-amino acids.
Type:
Grant
Filed:
September 24, 2004
Date of Patent:
February 20, 2007
Assignee:
Warner-Lambert Company LLC
Inventors:
Peter Garth Blazecka, Joseph Richard Bozelak, Norman Lloyd Colbry, Timothy Thomas Curran, Annise Paige Goodman, Kevin E. Henegar, Garrett Hoge, Paul D. Johnson, Augustine Tobi Osuma, Mark Stephen Plummer, Jacob Bradley Schwarz, Derek Clinton Vrieze, Ji Zhang
Abstract: This invention provides compounds defined by Formula I and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of treating osteo- and rheumatoid arthritis.
Type:
Grant
Filed:
August 5, 2003
Date of Patent:
February 20, 2007
Assignees:
Warner-Lambert Company, Warner-Lambert Company LLC
Inventors:
Amy Mae Bunker, Mark Anthony Morris, Patrick Michael O'Brien, Michael William Wilson
Inventors:
Cristina E. Bonaldes, Charles D. Denton, Heath A. Doty, Bryan Holmes, Marc Hunter, Victoria Noble, Randal D. Porter, Kim Sines, John E. Smethers, Russell Wright